Prometrium East Asian Safety Profile Differences: What Pharmacogenomics and Clinical Data Show

Updated Jan 28, 2025

Image: HealthRX.com clinical illustration

Prometrium is the brand name for oral micronized progesterone (100 mg and 200 mg capsules), FDA-approved for endometrial protection in postmenopausal women taking estrogen and for secondary amenorrhea. It is a bioidentical steroid hormone, not a synthetic progestin, and it is metabolized in the liver primarily through the enzyme CYP2C19. East Asian populations carry loss-of-function CYP2C19 alleles at a well-documented higher frequency than European populations, a pharmacogenomic difference cataloged by PharmGKB. Whether that population-level difference should change how Prometrium is dosed or monitored in an individual East Asian patient is a clinical judgment call that current published evidence does not fully resolve.

The core answer, with its boundary: CYP2C19 poor-metabolizer status is more common in East Asian populations than in European populations, and because CYP2C19 is a major clearance pathway for oral progesterone, reduced-function genotypes are pharmacologically plausible drivers of higher drug and allopregnanolone (the main sedating metabolite) exposure at a standard dose. No published, adequately powered randomized trial has specifically tested whether East Asian patients need a different Prometrium starting dose, so this remains a pharmacokinetic inference extrapolated from general CYP2C19 population genetics and small pharmacokinetic studies, not a guideline-endorsed dosing rule anchored in Prometrium-specific trial data in this population.

Why enzyme genetics matter here

Prometrium is absorbed largely intact and metabolized hepatically, with CYP2C19 doing much of the oxidative work. One resulting metabolite, allopregnanolone, is a positive allosteric modulator of GABA-A receptors and is the leading pharmacological explanation for the sedation, dizziness, and drowsiness that some patients report on oral progesterone. When the enzyme that clears the parent drug and shapes metabolite formation is underactive, exposure to progesterone and its neuroactive metabolites can be expected to rise for a given dose. This is a pharmacological mechanism, not a demonstrated clinical outcome specific to Prometrium.

CYP2C19 loss-of-function alleles, chiefly *2 and *3, are substantially more common in East Asian populations than in European populations. This is one of the most consistently replicated findings in human pharmacogenomics and underlies dosing guidance for other CYP2C19 substrates such as clopidogrel and some proton pump inhibitors. PharmGKB's CYP2C19 gene page documents this population difference and the enzyme's broader substrate list. Extending that established genetic fact to a specific numeric claim about Prometrium exposure in East Asian patients requires a Prometrium-specific pharmacokinetic study; the source material for this article did not include a verifiable, checkable citation for such a study, so precise percentage claims about how much higher East Asian exposure runs have been removed rather than presented as settled numbers.

Body composition may compound any enzymatic difference. Progesterone is lipophilic, and a smaller volume of distribution generally raises peak plasma concentration for an identical dose. This is basic pharmacokinetic reasoning rather than a population-specific trial finding, and it applies to any smaller-bodied patient regardless of ethnicity.

What the pivotal progesterone safety trial does and doesn't tell East Asian patients

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial is the most frequently cited randomized trial supporting micronized progesterone's endometrial safety and lipid profile when combined with estrogen. It was conducted in a predominantly white American cohort. Its endometrial-protection findings are strong evidence for the population it enrolled, but they do not by themselves establish that the same dose provides equivalent endometrial protection at different systemic exposure levels in a population with a different average metabolizer profile. This is a real evidence gap, not a reason to distrust the trial's findings for the population it studied.

What is not established: no published, prespecified East Asian subgroup analysis of Prometrium's pharmacokinetics or endometrial-protection endpoints exists in the material reviewed for this article. Claims that a specific percentage of East Asian women experience more sedation, or that AUC rises by a specific percentage in poor metabolizers, appeared in earlier drafts of this topic without a citation that could be independently verified against the primary literature. Rather than repeat an unverified number, this article states plainly that dedicated Prometrium pharmacokinetic and safety data in East Asian cohorts is limited and that patient-level monitoring should substitute for a population average the reader cannot verify.

Is CYP2C19 genetic testing worth doing before starting Prometrium?

Routine CYP2C19 genotyping is not standard of care before starting Prometrium. There is no CPIC (Clinical Pharmacogenetics Implementation Consortium) dosing guideline specific to progesterone the way there is for clopidogrel or certain antidepressants. Testing may still be a reasonable discussion in specific situations: a patient who develops significant sedation or next-day grogginess even at a low dose, a patient taking a known CYP2C19 inhibitor (omeprazole, fluconazole, fluvoxamine, and some other agents fall in this category and should be confirmed against current prescribing information), or a patient with a personal history of unusual drug sensitivity. These are situations where genotype information could plausibly inform a dose adjustment discussion with a prescriber, not situations where testing is required.

Population-specific evidence and transferability map

What this covers	Directly studied	Extrapolated / plausible	Needs specialist input	Outcome to monitor
CYP2C19 allele frequency, East Asian vs. European	Yes, broadly replicated population pharmacogenomic literature	,	,	Not applicable; this is background genetics, not a treatment outcome
CYP2C19's role in progesterone metabolism generally	Yes, established pharmacology of the enzyme and pathway	,	,	,
Higher Prometrium exposure specifically in East Asian poor metabolizers	No adequately powered, verifiable Prometrium-specific trial identified	Plausible by mechanism, drawn from general CYP2C19 pharmacogenomics	Pharmacogenomics-informed prescriber if sedation occurs	Patient-reported sedation, dizziness, cognitive fog in first 1-2 weeks
Whether a lower starting dose changes endometrial protection in East Asian women	Not established; no published subgroup data located	Assumed neutral to protective, based on general dose-response reasoning, not trial data	Gynecology or menopause specialist for dose decisions	Endometrial thickness on ultrasound; any breakthrough bleeding
HLA-B*15:02 relevance to Prometrium	Established as irrelevant by drug class reasoning (steroid hormone, not an aromatic-amine drug structurally linked to this allele's risk)	,	,	Not a monitoring priority for this drug
PPI (e.g., omeprazole) co-administration and CYP2C19 inhibition	CYP2C19 inhibition by omeprazole is an established pharmacological interaction in general	Combined effect with Prometrium specifically is inferred, not trial-confirmed	Prescriber managing both medications	New or worsened sedation after starting or changing a CYP2C19 inhibitor
Vaginal micronized progesterone as an alternative route for sedation-prone patients	Lower systemic exposure via vaginal route vs. oral is a recognized pharmacokinetic principle	Whether it resolves sedation while preserving endometrial protection at the individual level	Prescriber weighing route change	Sedation resolution and continued endometrial protection at follow-up

Practical guidance if sedation is a concern

Standard FDA-labeled Prometrium dosing is 200 mg orally once daily for 12 days per 28-day cycle in women on cyclic estrogen therapy, or 100 mg nightly on a continuous regimen; consult the current FDA-approved prescribing information for the complete label, since labeling can be revised. These doses were established in trial populations that were not predominantly East Asian, which is a reason for individualized attention rather than a reason to deviate from the label without clinical guidance.

If a patient reports sedation, dizziness, or next-day cognitive fog:

Confirm the dose is being taken at bedtime, which is already the manufacturer's guidance and allows peak sedating metabolite levels to coincide with sleep rather than waking hours.
Review concurrent medications for CYP2C19 inhibitors, particularly omeprazole or other PPIs, azole antifungals, or fluvoxamine.
Discuss with the prescriber whether a lower dose or a vaginal route of administration is appropriate; this is a prescribing decision that depends on the indication being treated and cannot be made from a general article.
Do not adjust or stop a hormone regimen without the prescriber's involvement, particularly when it is being used for endometrial protection alongside estrogen therapy, since unopposed estrogen carries its own established endometrial risk.

Prometrium capsules are formulated in peanut oil and are contraindicated in patients with peanut allergy. This applies to all patients regardless of ethnicity and is stated on the FDA label.

HLA-B*15:02 and Prometrium

HLA-B15:02 is an allele associated with severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) to certain drugs, most notably carbamazepine, and is more common in Han Chinese and some Southeast Asian populations than in European populations. Prometrium is a steroid hormone, structurally unrelated to the drug classes linked to HLA-B15:02-associated reactions. There is no established mechanistic or pharmacovigilance basis for concern about this allele with Prometrium. Patients can reasonably be told this allele is not relevant to Prometrium safety decisions, while recognizing that pharmacovigilance databases such as the FDA FAERS dashboard reflect voluntary reporting and cannot rule out very rare events.

What is established, what is plausible, and what is not established

Established: CYP2C19 loss-of-function alleles are more common in East Asian than European populations; CYP2C19 is a major metabolic pathway for oral progesterone; allopregnanolone is the metabolite most linked to sedation; Prometrium's FDA label dose was set primarily from studies not focused on East Asian populations; HLA-B*15:02 is not a recognized risk factor for Prometrium.

Plausible but unproven at the population level: that CYP2C19 poor-metabolizer status meaningfully raises Prometrium-related sedation risk in East Asian patients specifically, that a lower starting dose reduces sedation without compromising endometrial protection in this population, and that vaginal administration resolves sedation while preserving efficacy in East Asian patients specifically (the pharmacokinetic principle behind lower systemic exposure via the vaginal route is well established generally; its outcome in this population has not been separately confirmed here).

Not established: any specific numeric estimate of how much higher East Asian exposure or sedation rates run compared with other populations, based on a citation that could be verified for this article. Any such number should be treated as requiring verification against the primary literature before being used in patient counseling.

When to seek urgent care

Sedation and dizziness from progesterone are generally not medical emergencies, but any of the following warrant prompt contact with a prescriber or urgent evaluation: heavy or irregular vaginal bleeding while on hormone therapy, signs of an allergic reaction (swelling, difficulty breathing, hives) which could relate to the peanut oil excipient, severe dizziness affecting safety (for example, while driving), or new chest pain, leg swelling, or shortness of breath, which are not established side effects of progesterone itself but warrant evaluation given estrogen-progestogen therapy's broader risk profile.

Frequently asked questions

Does Prometrium work differently in East Asian patients?

It may. East Asian populations carry CYP2C19 loss-of-function alleles more often than European populations, and CYP2C19 is a primary enzyme clearing oral progesterone. This is an established genetic difference and a plausible mechanism for higher exposure in some individuals, but no verifiable Prometrium-specific trial in East Asian patients was identified to confirm the size of that effect.

What is the standard Prometrium dose, and was it studied in East Asian patients?

The FDA-approved dose is 200 mg daily for 12 days per 28-day cycle, or 100 mg nightly continuously, per the current prescribing information. The pivotal trials establishing this dosing, including PEPI, were conducted predominantly in non-Asian populations, so individualized monitoring is reasonable rather than assuming the dose behaves identically across all patients.

Should East Asian women get CYP2C19 testing before starting Prometrium?

Routine testing is not standard of care. It may be worth discussing with a prescriber if sedation occurs at standard doses, if the patient takes a CYP2C19 inhibitor such as omeprazole, or if there is a history of unusual drug sensitivity.

Does bedtime dosing help with sedation?

Taking Prometrium at bedtime, already the manufacturer's recommendation, allows peak sedating metabolite levels to occur during sleep rather than during waking hours, which is a reasonable first step for anyone experiencing sedation regardless of ethnicity.

Is vaginal progesterone a safer alternative for people who get sedated on oral Prometrium?

Vaginal administration produces lower systemic exposure than oral dosing because it partially bypasses first-pass liver metabolism, a recognized pharmacokinetic principle. Whether it fully preserves endometrial protection for a given patient is a decision that should be made with a prescriber, not from a general article.

Is HLA-B*15:02 relevant to Prometrium safety?

No. That allele is linked to severe skin reactions from specific drugs such as carbamazepine. Prometrium is a steroid hormone with a different chemical structure, and there is no established mechanism connecting it to HLA-B*15:02-related reactions.

Can proton pump inhibitors like omeprazole affect Prometrium levels?

Omeprazole is a recognized CYP2C19 inhibitor. Since CYP2C19 also clears progesterone, taking both together is a plausible reason for increased sedation, and this combination is worth mentioning to a prescriber, though a Prometrium-specific interaction study was not identified for this article.

References

PharmGKB. CYP2C19 gene page. https://www.pharmgkb.org/gene/PA124
U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard

Other claims in earlier drafts of this article cited specific PubMed identifiers (PEPI trial results, allele frequency percentages, sedation rate comparisons, an internal cohort figure, and a direct quotation attributed to a named researcher) that could not be verified against the primary literature for this revision. Those figures and the quotation have been removed or converted to general, unverified-pending-review statements rather than presented as sourced facts. A qualified reviewer with database access should confirm or restore specific citations before publication.